Capivasertib with fulvestrant for HR+/HER2- locally advanced or metastatic breast cancer

Capivasertib with fulvestrant is in development for the treatment of patients with locally advanced (inoperable) or metastatic Hormone Receptor-Positive (HR+) and Human Epidermal growth factor Receptor 2-Negative (HER2-) breast cancer. A locally advanced breast cancer is stage 3, where cancer has spread from the breast to areas close to the breast or to the chest wall. Metastatic breast cancer is stage 4, where the cancer has spread to other parts of the body. HR+ breast cancer has either or both the oestrogen and progesterone sex hormone receptors (receptors are proteins within or on body cells). HER2 is a protein that helps breast cancer cells grow quickly. HER2- breast cancers have zero to normal levels of the HER2 protein. The symptoms may include; breast lump, breast swelling, breast or nipple pain, and bloody nipple discharge.